Retention Sample in Pharmaceutical QC: Complete Guide for QC Professionals

In a pharmaceutical manufacturing company, testing a batch before release is not always the end of quality control. A company may need to examine the same batch again months or even years later because of a market complaint, product defect, investigation, recall, or regulatory requirement.

This is where a retention sample becomes important. A retention sample is a representative portion of a pharmaceutical batch that is kept under suitable conditions so that it remains available for future examination. It gives the quality team a physical reference of the batch that was manufactured and released.

For a QC professional, retention samples are particularly useful during investigations because the original batch may no longer be available at the manufacturing site. A properly identified and stored sample can provide valuable evidence when investigating a quality concern.

What is a retention sample?

A retention sample is a sample taken from a batch and kept for possible future evaluation.

For finished pharmaceutical products, the sample is normally maintained in its final packaging, where practical. WHO GMP guidance states that finished-product retention samples should be kept under recommended storage conditions and in the final packaging, with sufficient quantity for appropriate re-examination.

Retention Sample in Pharmaceutical QC

For example, suppose a company manufactures 50,000 bottles of tablets. After manufacturing, packaging and QC testing, the batch is released.

A defined number of bottles from that batch may be placed in the retention sample area.

The retained bottles are not simply extra stock. They are controlled samples associated with a particular batch and are kept for a specific quality-management purpose.

Why does pharmaceutical QC keep retention samples?

The main purpose is to have physical material available if the quality of a released batch needs to be checked later.

Consider a simple situation.

A batch of tablets is released in January. Six months later, a customer reports that some tablets have developed an unusual appearance.

The investigation team needs to determine whether the problem may be related to the manufacturing batch, packaging, transportation, storage, or another factor.

If a properly stored retention sample is available from the same batch, the company can examine it and compare the findings with the complaint information.

Retention samples may therefore support:

• Market complaint investigations
• Product quality investigations
• Recall investigations
• Packaging or labeling investigations
• Identification of a particular batch
• Assessment of suspected physical changes
• Regulatory inspections
• Investigation of unexpected quality observations

The sample does not automatically prove the cause of a problem. It is one piece of evidence that should be evaluated together with manufacturing records, laboratory results, stability data, complaint samples and other relevant information.

Retention sample and stability sample are not the same

These two terms are sometimes used incorrectly.

A retention sample is mainly kept so that a batch can be examined in the future when there is a justified need.

A stability sample, on the other hand, is part of a planned stability programme. It is tested at predefined intervals to generate information about the product's stability over time.

ICH Q7 specifically distinguishes reserve samples from stability samples for APIs. Reserve samples are intended for possible future evaluation of batch quality and are not intended to replace stability testing.

Therefore:

Retention sample = future examination/reference

Stability sample = planned stability study

Both are important, but they serve different purposes.

For a detailed understanding of stability work, QC professionals can also read the relevant pharmaceutical QC and analytical articles on my site.

What products are retained?

The exact requirements depend on the applicable GMP requirements, product category and company procedure.

Retention samples may be maintained for:

• Finished pharmaceutical products
• Active pharmaceutical ingredients
• Certain starting materials
• Intermediates, where required
• Other materials specified by the company's quality system

The procedure should clearly identify which materials need to be retained.

It is not advisable to create one general rule for every material because regulatory requirements can differ.

For example, ICH Q7 contains specific requirements for reserve samples of APIs.

How is a retention sample collected?

The sample should be collected according to an approved sampling procedure.

It should be representative of the relevant batch and should be protected against contamination, deterioration and mix-up during collection.

The sampling procedure may define:

• Product name
• Batch or lot number
• Quantity to be collected
• Sampling location
• Sampling method
• Packaging requirements
• Identification details
• Storage conditions
• Person responsible for sampling
• Sampling date

The quantity should be sufficient for the examinations that may reasonably be required.

WHO guidance states that retention samples of materials and products should be sufficient to permit at least two full re-examinations.

The exact quantity used by a company should therefore be established through its approved procedure and applicable requirements.

What information should be present on the sample?

Traceability is one of the most important parts of retention-sample management.

A person should be able to look at the retention record and understand exactly which batch the sample belongs to.

Typical information may include:

• Product name
• Strength
• Dosage form
• Batch number
• Manufacturing date
• Expiry date
• Sample quantity
• Storage condition
• Sampling date
• Retention sample number
• Storage location

Additional information may be maintained in an electronic system or retention-sample register.

The important thing is that the physical sample and its record remain clearly connected.

Packaging of retention samples

The packaging should protect the sample from unnecessary exposure to environmental conditions.

For a finished product, keeping the sample in the same final packaging as the marketed product is generally preferred where practical.

For example, if tablets are marketed in a blister pack, the retained sample may be kept in that same type of packaging.

WHO guidance states that finished products should usually be retained in their final packaging and stored under the recommended conditions.

For APIs, ICH Q7 states that reserve samples should be stored in the same packaging system used for the API or in packaging that is equivalent or more protective.

Storage conditions

A retention sample is useful only if it remains suitable for examination.

For this reason, storage conditions should be controlled according to the applicable product requirements.

Depending on the product, the sample may require:

• Controlled room temperature
• Refrigerated conditions
• Frozen conditions
• Protection from light
• Humidity control
• Other specified environmental conditions

The retention area should also be organized so that samples can be located without difficulty.

Where environmental monitoring is required, temperature and other relevant conditions should be recorded.

Poor storage can create a problem during an investigation. If a sample has been exposed to unsuitable conditions, it may no longer provide a reliable comparison with the original batch.

Retention sample storage area

A company should have a suitable location for retained materials.

The area should provide:

• Adequate storage capacity
• Proper identification
• Suitable environmental conditions
• Restricted access
• Protection against contamination
• Protection against mix-ups
• Easy retrieval
• Inventory control

A retention sample register can be maintained manually or electronically.

For example:

Product	Batch No.	Expiry	Quantity	Storage Location
Paracetamol Tablets 500 mg	PCT25001	2027	10 strips	Rack A-02
Product B	PB25007	2028	5 bottles	Rack B-04

The actual quantity and storage arrangement should always follow the company's approved SOP.

How long should retention samples be kept?

This is an area where QC professionals should avoid using one number for every product.

The retention period depends on the applicable GMP requirement, material type, regulatory market and company procedure.

For finished pharmaceutical products, WHO GMP guidance states that retention samples from each batch should be kept for at least one year after the expiry date. It also states that samples should be sufficient for at least two full re-examinations.

For APIs, ICH Q7 has a different specific requirement: reserve samples should generally be retained for one year after the assigned expiry date or three years after distribution, whichever is longer. For APIs with retest dates, the corresponding reserve samples should generally be retained for three years after complete distribution.

Therefore, the correct approach is: Follow the current applicable regulatory requirement and the company's approved SOP rather than assuming one retention period applies to everything.

This distinction is important when preparing or reviewing a pharmaceutical QC procedure.

When is a retention sample used?

A retained sample may remain untouched for a long time.

It may only be retrieved when there is a legitimate reason.

Common situations include:

Market complaint

A customer reports a suspected defect.

The investigation team may compare the complaint with a retained unit from the same batch.

Product recall

If a quality defect results in recall activity, retained material may help the company evaluate the affected batch.

Packaging problem

A complaint may involve broken containers, leakage, discoloration or another packaging-related issue.

The retained pack can be examined along with packaging records.

Identification concern

If there is doubt about a product or batch, the retained sample can provide a physical reference.

Quality investigation

A retained unit may be examined when a broader investigation requires additional evidence.

Retention sample during an OOS investigation

Retention samples can sometimes become relevant during an Out-of-Specification (OOS) investigation.

However, they should not be used simply to obtain another result after an OOS result is obtained.

Any additional examination should have a documented scientific and procedural justification.

If an investigation genuinely requires examination of retained material, the work should be performed according to the approved investigation procedure.

Article on OOS Investigation in the Pharmaceutical Industry explains the investigation process, root-cause assessment, retesting, resampling and CAPA in more detail.

The retained sample is therefore supporting evidence, not a shortcut for invalidating an original laboratory result.

Connection with CAPA

Sometimes an investigation involving a retained sample identifies a broader quality-system issue.

For example, an investigation could identify a problem involving:

• Sampling
• Packaging
• Storage
• Documentation
• Manufacturing
• Laboratory testing
• Equipment
• Training

If a systemic problem is identified, appropriate corrective and preventive action may be required.

 CAPA-related pharmaceutical quality content can be used as a related resource when explaining how investigation findings can lead to corrective action.

Retention samples and change control

Changes to the retention system should also be controlled.

Suppose a company wants to move its retention samples to a different storage room.

The change may affect:

• Temperature monitoring
• Humidity
• Security
• Sample retrieval
• Storage capacity
• Sample traceability

Such changes should be evaluated through the company's change-control system.

Article on Change Control in the Pharmaceutical Industry provides a useful explanation of how planned changes are assessed and documented.

Good documentation is essential

A retention sample is not properly controlled simply because it has been placed on a shelf.

The associated records should allow the company to answer questions such as:

• Which batch was retained?
• When was the sample collected?
• Who collected it?
• How much was retained?
• Where is it stored?
• Under what conditions?
• Has it been removed?
• Why was it removed?
• Was testing performed?
• When can it be disposed of?

This is why good documentation practices are closely connected with sample management.

For additional reading, see a article on Good Laboratory Practice in the Pharmaceutical QC Laboratory.

Common mistakes in retention sample management

Even a simple retention system can fail if basic controls are ignored.

Wrong identification

A wrong batch number can make the sample practically useless during an investigation.

Poor storage

Unsuitable environmental conditions may alter the material.

Insufficient quantity

The retained quantity may not be enough for the required examination.

Mixing batches

Samples from different lots should remain clearly separated.

Uncontrolled access

Removal of a sample should be documented and authorized.

Missing records

A company should be able to trace every retained sample.

Early disposal

Samples should not be discarded before the approved retention period ends.

Using retention samples as stability samples

These two sample types have different purposes and should be managed accordingly.

Simple example from a QC laboratory

Imagine that a company releases a batch of 500 mg tablets.

After completion of manufacturing, packaging and QC testing, the required number of units is placed in the retention area.

The sample is identified with the product and batch details and stored under the specified conditions.

Several months later, a complaint is received stating that tablets from this batch have an unusual appearance.

The investigation team retrieves the retained sample.

They may examine the tablets visually and, depending on the investigation, perform appropriate additional testing.

The results are then considered alongside the complaint sample, batch manufacturing records, packaging information, release results and stability data.

If the retained units show no similar defect, that information becomes part of the investigation. It does not automatically close the complaint, but it can help the team assess possible causes.

This is the real value of a retention sample: it provides physical evidence from the original batch when that evidence may otherwise be unavailable.

Retention sample vs reference sample

The terms retention sample and reference sample can have different meanings depending on the applicable GMP framework.

In some systems, a retention sample is primarily associated with identification and future examination, while a reference sample may be intended for analytical testing.

The terminology should therefore be defined clearly in the company's SOP rather than assuming that the terms mean exactly the same thing everywhere.

This is particularly important for biological products, APIs and other specialized materials, where regulatory guidance may define the terms differently.

What should a QC analyst remember?

The most important points are simple:

1. Keep a representative sample from the required batches.
2. Identify it correctly.
3. Protect it from deterioration.
4. Store it under the required conditions.
5. Maintain complete traceability.
6. Control access to the storage area.
7. Retrieve samples only for justified reasons.
8. Document any examination or removal.
9. Follow the applicable retention period.
10. Never treat the retention sample as a replacement for stability testing.

Conclusion

Retention samples are an important part of pharmaceutical quality management. They provide a physical connection to a batch even after the product has been released and distributed.

When a complaint, recall or quality investigation occurs, the retained material can provide useful evidence about the condition and identity of the original batch.

A good retention system therefore depends on more than storing a few extra units. Sampling, identification, packaging, storage, traceability, access control, documentation and disposal all need to be managed through an appropriate quality system.

For QC professionals, the key principle is simple: retain the right sample, protect it properly, maintain its traceability, and make it available when a justified investigation requires it.

Always check the latest applicable GMP and regulatory requirements before establishing or revising a retention-sample procedure.

References

1. World Health Organization. WHO Good Manufacturing Practices for Pharmaceutical Products, Technical Report Series No. 986, Annex 2.
2. International Council for Harmonisation (ICH). Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, Section 11.7 – Reserve/Retention Samples.
3. U.S. Food and Drug Administration. Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients.
4. World Health Organization. WHO Guidelines on Stability Testing of Active Pharmaceutical Ingredients and Finished Pharmaceutical Products.
5. World Health Organization. WHO Good Practices for Pharmaceutical Quality Control Laboratories.

Disclaimer: This article is for educational purposes. Specific sample quantities, storage conditions and retention periods should be established according to the current applicable regulatory requirements and the pharmaceutical company's approved SOP.